Tipifarnib (ZARNESTRA (TM)) and imatinib (GLEEVEC (TM)) combination therapy in patients with advanced chronic myelogenous leukemia (CML): Preliminary results of a phase I study. Gotlib, J., Mauro, M., O'Dwyer, M. E., Fechter, L., Dugan, K., Kuyl, J., Yekrang, A., Mori, M., Rackoff, W., Coutre, S., Druker, B., Greenberg, P. L. AMER SOC HEMATOLOGY. 2003: 909A–910A

View details for Web of Science ID 000186536703384